David Roman
Stock Analyst at Goldman Sachs
(1.67)
# 3,007
Out of 4,792 analysts
35
Total ratings
30%
Success rate
-8.27%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KMTS Kestra Medical Technologies | Initiates: Neutral | $24 | $23.42 | +2.50% | 1 | Mar 31, 2025 | |
| HQY HealthEquity | Maintains: Neutral | $107 → $94 | $84.34 | +11.45% | 2 | Mar 27, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $85 → $100 | $72.05 | +38.79% | 2 | Mar 11, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $138 → $154 | $132.53 | +16.20% | 2 | Mar 4, 2025 | |
| TDOC Teladoc Health | Maintains: Buy | $16 → $13 | $7.65 | +69.89% | 3 | Mar 3, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $42 → $24 | $17.61 | +36.32% | 2 | Mar 3, 2025 | |
| SOLV Solventum | Maintains: Sell | $63 → $71 | $73.24 | -3.05% | 4 | Mar 3, 2025 | |
| LIVN LivaNova | Maintains: Buy | $64 → $55 | $37.89 | +45.18% | 2 | Mar 3, 2025 | |
| BAX Baxter International | Reinstates: Buy | $42 | $31.60 | +32.91% | 3 | Feb 26, 2025 | |
| IRTC iRhythm Technologies | Maintains: Neutral | $91 → $124 | $103.71 | +19.56% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $80 | $55.44 | +44.31% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $384 → $427 | $369.35 | +15.61% | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $90 | $72.49 | +24.16% | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $99.36 | -9.42% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $500 | $502.88 | -0.57% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $274 | $221.73 | +23.57% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $129 | $113.25 | +13.91% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $83 | $88.21 | -5.91% | 1 | May 30, 2024 |
Kestra Medical Technologies
Mar 31, 2025
Initiates: Neutral
Price Target: $24
Current: $23.42
Upside: +2.50%
HealthEquity
Mar 27, 2025
Maintains: Neutral
Price Target: $107 → $94
Current: $84.34
Upside: +11.45%
GE HealthCare Technologies
Mar 11, 2025
Upgrades: Buy
Price Target: $85 → $100
Current: $72.05
Upside: +38.79%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $138 → $154
Current: $132.53
Upside: +16.20%
Teladoc Health
Mar 3, 2025
Maintains: Buy
Price Target: $16 → $13
Current: $7.65
Upside: +69.89%
Tandem Diabetes Care
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $24
Current: $17.61
Upside: +36.32%
Solventum
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $73.24
Upside: -3.05%
LivaNova
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $37.89
Upside: +45.18%
Baxter International
Feb 26, 2025
Reinstates: Buy
Price Target: $42
Current: $31.60
Upside: +32.91%
iRhythm Technologies
Feb 24, 2025
Maintains: Neutral
Price Target: $91 → $124
Current: $103.71
Upside: +19.56%
Feb 10, 2025
Maintains: Neutral
Price Target: $58 → $80
Current: $55.44
Upside: +44.31%
Jan 30, 2025
Maintains: Neutral
Price Target: $384 → $427
Current: $369.35
Upside: +15.61%
Dec 5, 2024
Maintains: Buy
Price Target: $81 → $90
Current: $72.49
Upside: +24.16%
May 30, 2024
Initiates: Buy
Price Target: $90
Current: $99.36
Upside: -9.42%
May 30, 2024
Initiates: Buy
Price Target: $500
Current: $502.88
Upside: -0.57%
May 30, 2024
Initiates: Buy
Price Target: $274
Current: $221.73
Upside: +23.57%
May 30, 2024
Initiates: Neutral
Price Target: $129
Current: $113.25
Upside: +13.91%
May 30, 2024
Initiates: Sell
Price Target: $83
Current: $88.21
Upside: -5.91%